A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia (BRIGHT AML1019)
研究单位：[1]Pfizer[2]Tongji Hospital,Tongji Medical College,Huazhong University of Science & Technology/Cancer Center Wuhan,Hubei,China,430030[3]Henan Provincial People's Hospital/Hematology Department Zhengzhou,Henan,China,450003[4]Henan Cancer Hospital Zhengzhou,Henan,China,450008[5]Institute of Hematology and Blood Diseases Hospital,Chinese Academy of Medical Sciences Tianjin,Tianjin,China,300020[6]The First Affiliated Hospital College of Medicine,Zhejiang University Hangzhou,Zhejiang,China,310003
研究目的：
Glasdegib is being studied in combination with azacitidine for the treatment of adult patients with previously untreated acute myeloid leukemia (AML) who are not candidates for intensive induction chemotherapy (Non-intensive AML population).
Glasdegib is being studied in combination with cytarabine and daunorubicin for the treatment of adult patients with previously untreated acute myeloid leukemia (Intensive AML population).
